OTOV101N OTOV101C
Alternative Names: OTOV101C+OTOV101NLatest Information Update: 23 Aug 2023
At a glance
- Originator Otovia Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Deafness
Most Recent Events
- 26 Jun 2023 Clinical trials in Deafness (In children, In adolescents, In adults, In the elderly) in China (Otic) (NCT05901480)
- 13 Jun 2023 Preclinical trials in Deafness (Otic) prior to June 2023
- 13 Jun 2023 Otovia Therapeutics plans a clinical trial for Deafness in unknown location (NCT05901480)